CSIMarket
 


Enanta Pharmaceuticals Inc   (ENTA)
Other Ticker:  
 
 

ENTA's Capital Expenditures Growth by Quarter and Year

Enanta Pharmaceuticals Inc 's Capital Expenditures results by quarter and year




ENTA Capital Expenditures (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter September - 0.30 0.62 0.23
III Quarter June - 2.23 1.10 0.74
II Quarter March 0.35 2.51 0.75 0.58
I Quarter December 0.49 0.38 0.50 0.95
FY   0.84 5.42 2.97 2.50



ENTA Capital Expenditures second quarter 2020 Y/Y Growth Comment
Enanta Pharmaceuticals Inc reported drop in Capital Expenditures in the second quarter by -85.9% to $ 0.35 millions, from the same quarter in 2019.
The fall in the second quarter Enanta Pharmaceuticals Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 239.05%.

Looking into second quarter results within Major Pharmaceutical Preparations industry 155 other companies have achieved higher Capital Expenditures growth. While Enanta Pharmaceuticals Inc ' s Capital Expenditures meltdown of -85.9% ranks overall at the positon no. 2660 in the second quarter.




ENTA Capital Expenditures ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter September - -51.61 % 169.57 % -45.24 %
III Quarter June - 102.73 % 48.65 % 21.31 %
II Quarter March -85.9 % 234.67 % 29.31 % -61.59 %
I Quarter December 28.95 % -24 % -47.37 % -56.82 %
FY   - 82.49 % 18.8 % -47.26 %

Financial Statements
Enanta Pharmaceuticals Inc 's second quarter 2020 Capital Expenditures $ 0.35 millions ENTA's Income Statement
Enanta Pharmaceuticals Inc 's second quarter 2019 Capital Expenditures $ 2.51 millions Quarterly ENTA's Income Statement
New: More ENTA's historic Capital Expenditures Growth >>


ENTA Capital Expenditures (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter September - -86.55 % -43.64 % -68.92 %
III Quarter June - -11.16 % 46.67 % 27.59 %
II Quarter March -27.76 % 560.53 % 50 % -38.95 %
I Quarter December 63.33 % -38.71 % 117.39 % 126.19 %
FY (Year on Year)   - 82.49 % 18.8 % -47.26 %




Capital Expenditures second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #156
Healthcare Sector #440
Overall #2660

Capital Expenditures Y/Y Growth Statistics
High Average Low
1920.83 % 239.05 % -85.88 %
(Sep 30 2014)   (Mar 31 2020)
Capital Expenditures second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #156
Healthcare Sector #440
Overall #2660
Capital Expenditures Y/Y Growth Statistics
High Average Low
1920.83 % 239.05 % -85.88 %
(Sep 30 2014)   (Mar 31 2020)

Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Enanta Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
552.86 % 67.64 % -86.73 %
(Mar 31 2019)  


ENTA's II. Quarter Q/Q Capital Expenditures Comment
In the II. Quarter 2020 Enanta Pharmaceuticals Inc reported fall in Capital Expenditures from the previous quarter by -27.76% to $ 0.35 millions, from $ 0.49 millions released in the previous reporting period.

Although seasonal influence commonly fuel II. Quarter 2020 performance, this clearly has not been sufficient to salvage ENTA's II. Quarter achievement, Pablo Marín, market insider based in Madrid wrote and continued that average sequential Capital Expenditures growth is at 67.64% for ENTA.

Within Major Pharmaceutical Preparations industry 101 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Enanta Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1657.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #102
Healthcare Sector #277
Overall #1657
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #102
Healthcare Sector #277
Overall #1657
Capital Expenditures Q/Q Growth Statistics
High Average Low
552.86 % 67.64 % -86.73 %
(Mar 31 2019)  


ENTA's II. Quarter Q/Q Capital Expenditures Comment
In the II. Quarter 2020 Enanta Pharmaceuticals Inc disclosed fall in Capital Expenditures sequentially by -27.76% to $ 0.35 millions, from $ 0.49 millions released a quarter before.

Those periodic factors have not salvage the II. Quarter for the Enanta Pharmaceuticals Inc , Pablo Marín, market insider based in Madrid wrote, he cited some caution towards ENTA's direction, he detected new difficulties ahead for ENTA and continued that average quarter on quarter Capital Expenditures growth is at 67.64% for ENTA.

Within Major Pharmaceutical Preparations industry 101 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Enanta Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1657.


Enanta Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
Cumulative Capital Expenditures 12 Months Ending $ 3.37 $ 5.52 $ 5.42 $ 5.74 $ 4.62
Y / Y Capital Expenditures Growth (TTM) -27.04 % 92.97 % 81.72 % 121.6 % 106.9 %
Year on Year Capital Expenditures Growth Overall Ranking # 1970 # 475 # 553 # 396 # 450
Seqeuential Capital Expenditures Change (TTM) -39 % 1.92 % -5.69 % 24.44 % 61.34 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2631 # 1494 # 2340 # 488 # 157




Cumulative Capital Expenditures growth Comment
For the 12 months ended Mar 31 2020 Enanta Pharmaceuticals Inc reported a drop in Capital Expenditures by -27.04% year on year, to $3 millions, compare to the 92.97% growth at Dec 31 2019.

In the Healthcare sector 282 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 475 to 1970.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
88.24 %
9.79 %
-39 %
(Sep. 30, 2015)  

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 92
Healthcare Sector # 283
Overall # 1959

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
375.66 %
79.58 %
-55.03 %
(June 30. 2016)  


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 428
S&P 500 # 2616
Cumulative Capital Expenditures growth Comment
For the 12 months ended Mar 31 2020 Enanta Pharmaceuticals Inc reported a drop in Capital Expenditures by -27.04% year on year, to $3 millions, compare to the 92.97% growth at Dec 31 2019.

In the Healthcare sector 282 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 475 to 1970.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
88.24 %
9.79 %
-39 %
(Sep. 30, 2015)  


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 92
Healthcare Sector # 283
Overall # 1959

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
375.66 %
79.58 %
-55.03 %
(June 30. 2016)  


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 428
S&P 500 # 2616




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ENTA's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ENTA's Competitors
Capital Expenditures Growth for Enanta Pharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for ENTA's Customers

You may also want to know
ENTA's Annual Growth Rates ENTA's Profitability Ratios ENTA's Asset Turnover Ratio ENTA's Dividend Growth
ENTA's Roe ENTA's Valuation Ratios ENTA's Financial Strength Ratios ENTA's Dividend Payout Ratio
ENTA's Roa ENTA's Inventory Turnover Ratio ENTA's Growth Rates ENTA's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2020
Orasure Technologies Inc -1.26 %$ -1.256 millions
Beigene Ltd -1.35 %$ -1.351 millions
Spero Therapeutics Inc -2.47 %$ -2.469 millions
Neuronetics Inc -2.92 %$ -2.920 millions
Myriad Genetics Inc -3.23 %$ -3.226 millions
Celcuity Inc -4.28 %$ -4.276 millions
Kaleido Biosciences Inc -4.53 %$ -4.529 millions
Standard Diversified Inc -4.67 %$ -4.674 millions
Johnson and Johnson -4.73 %$ -4.726 millions
Fibrogen Inc -4.97 %$ -4.969 millions
Vanda Pharmaceuticals Inc -5.09 %$ -5.089 millions
Tenet Healthcare Corp -5.15 %$ -5.155 millions
Hanger Inc -5.38 %$ -5.379 millions
Endologix Inc -6.54 %$ -6.542 millions
Intuitive Surgical Inc -8.36 %$ -8.362 millions
Bristol Myers Squibb Co -8.82 %$ -8.824 millions
Dynatronics Corp -8.92 %$ -8.923 millions
Integrated Biopharma Inc -9.52 %$ -9.524 millions
Viveve Medical Inc -10.06 %$ -10.056 millions
Heska Corp -10.26 %$ -10.256 millions
Icu Medical Inc -10.45 %$ -10.447 millions
Milestone Scientific Inc -11.92 %$ -11.920 millions
Veracyte Inc -13.07 %$ -13.072 millions
Baxter International Inc -13.13 %$ -13.131 millions
Eventbrite Inc -13.22 %$ -13.215 millions
Blueprint Medicines Corporation -13.84 %$ -13.842 millions
Dexcom Inc -15.52 %$ -15.522 millions
Mettler Toledo International Inc -15.93 %$ -15.930 millions
Teleflex Incorporated -16.22 %$ -16.217 millions
Alkermes Plc -16.24 %$ -16.244 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ACER's Profile

Stock Price

ACER's Financials

Business Description

Fundamentals

Charts & Quotes

ACER's News

Suppliers

ACER's Competitors

Customers & Markets

Economic Indicators

ACER's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071